Keywords:
Oncology, Pelvis, PET, Audit and standards, Outcomes
Authors:
R. Smith, M. Winkel, J. Filby, G. Evans, S. Antoniou, P. Smith, S. Pridgeon; Cairns/AU
DOI:
10.1594/ranzcr2018/R-0104
Results
62 patients were imaged with 68Ga-PSMA-PET-CT and 1 patient with whole body PSMA-PET-MRI between August 2015 to April 2017.
All decisions for imaging were undertaken at a multidisciplinary team level with all results subsequently reviewed at the meeting. Indications for imaging were primary staging (n=35) and investigation of biochemical recurrence (n=28).
For primary staging,
PSMA-PET was indicated when conventional staging imaging was inconclusive (n=16) or in patients at risk for metastases with normal conventional staging (n=19).
Of the 19 patients with normal conventional staging,
metastatic disease was diagnosed in 4 (21%) resulting in a change from active to palliative treatment.
8 (50%) with inconclusive conventional imaging were confirmed to have distant disease.
PSMA-PET was also utilised in the localisation of recurrence after primary treatment.
For biochemical failure,
the rate of detection of lesions for PSA <0.2 mcg/l ,
0.2–1.0 mcg/l,
1.0-2.0 mcg/l and >2.0 mcg/l were 0%,
25%,
0% and 92%,
respectively.
Localisation of metastatic lesions had a significant impact on treatment in all cases.